Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 5.16 2.99% 0.15
ALNA closed down 4.39 percent on Friday, October 18, 2019, on 2.0 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ALNA trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 2.99%
Inside Day Range Contraction 2.99%
Wide Bands Range Expansion 2.99%
Overbought Stochastic Strength 2.99%
Upper Bollinger Band Touch Strength 2.99%
New Uptrend Bullish -1.53%
Pocket Pivot Bullish Swing Setup -1.53%
Volume Surge Other -1.53%
Upper Bollinger Band Walk Strength -1.53%
Wide Bands Range Expansion -1.53%

Older signals for ALNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
Is ALNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.66
52 Week Low 3.33
Average Volume 82,011
200-Day Moving Average 5.5441
50-Day Moving Average 4.1946
20-Day Moving Average 4.27
10-Day Moving Average 4.581
Average True Range 0.3796
ADX 27.27
+DI 32.6997
-DI 9.7676
Chandelier Exit (Long, 3 ATRs ) 4.2512
Chandelier Exit (Short, 3 ATRs ) 4.4688
Upper Bollinger Band 5.1205
Lower Bollinger Band 3.4195
Percent B (%b) 0.94
BandWidth 39.836066
MACD Line 0.1924
MACD Signal Line 0.0796
MACD Histogram 0.1128
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.58
Resistance 3 (R3) 5.60 5.42 5.49
Resistance 2 (R2) 5.42 5.28 5.42 5.45
Resistance 1 (R1) 5.22 5.19 5.13 5.20 5.42
Pivot Point 5.04 5.04 5.00 5.04 5.04
Support 1 (S1) 4.84 4.90 4.75 4.82 4.60
Support 2 (S2) 4.66 4.81 4.66 4.57
Support 3 (S3) 4.46 4.66 4.54
Support 4 (S4) 4.44